Project Description

Cannabichromene (abbreviated as CBC) is a cannabinoid found in the cannabis plant. It bears structural similarity to the other cannabinoids, including tetrahydrocannabinol, tetrahydrocannabivarin, cannabidiol, and cannabinol, among others. Evidence has suggested that it may play a role in the anti-inflammatory and anti-viral effects of cannabis, and may contribute to the overall analgesic effects of medical marijuana. However, more research into the compound may be needed before any definitive medical effects can be verified.

Surprisingly, CBC is more abundant than CBD in some cannabis strains, despite its relative unfamiliarity. And while CBD may be the most medically studied and effective cannabinoid discovered to date, CBC appears to have a wealth of potential medicinal benefits:

– Recent studies have indicated that CBC can reduce inflammation, specifically in the intestinal tract. Strangely, CBC reduced inflammation without binding onto cannabinoid receptors in the test patients body. This has lead scientists to believe that combining CBC with other cannabinoids that do latch onto receptors could hold powerful, holistic medical value.

– A now 30 year old study revealed that CBC had powerful anti-bacterial effects on a wide array of bacteria including E-coli and Staph.

– A 2013 research report suggested that CBC may actually help in neurological development, especially neurogenesis, literally the process of new brain cell production. Recent findings have dismissed the long considered truth that neurogenesis only occurs during foetal development. New brain cell production continues in adult mammals in the hippocampus region of the brain, an area linked to memory and the retaining of information. A default in the hippocampus region is associated with neuro-degenerative diseases such as Alzheimers, leading many to believe that CBC’s ability to increase neurogenesis in this area of the brain could be a solution for the aforementioned ailments.

– A 2011 study by the British Journal of Pharmacology suggested that CBC alleviated pain in test animals. The intensity of pain relief was not as high as THC, however the non-psychoactive properties of CBC could make it a far more applicable option for long term cannabinoid-enduced pain relief.

– A study by the University of Missisippi indentified CBC to have relatively strong anti-depressant properties. However, the study could not verify how CBC releases these properties on the body, since it does not interact with the brain in the same way as other anti-depressive cannabinoids (THC).

Official Research Reports

The effect of cannabichromene on adult neural stem/progenitor cells. (Shinjyo N, Di Marzo V, 2013)

The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. (Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M, Pertwee R, Coppola D, Vassallo L, Orlando P, Di Marzo V, Izzo A, 2013)

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. (Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, de Novellis V, Di Marzo V, 2011)

Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. (El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D, Khan I, ElSohly M, Ross S, 2010)

Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. (DeLong GT, Wolf CE, Poklis A, Lichtman AH, 2010)

Biological activity of cannabichromene, its homologs and isomers. (Turner CE, Elsohly MA, 1981)